Abstract
Mitochondria play a key role in intracellular energy-generating processes, cell life and death, and are heavily involved in several metabolic pathways by integrating signaling networks; thus, a very large number of conditions are characterized by mitochondrial bioenergetic in humans. Often, mitochondrial changes are directly or indirectly dependent on the activation of intracellular stress cascades or death receptor-mediated pathways. Reactive oxygen species (ROS) formation, glutathione (GSH) depletion, protein alkylation and respiratory complex alterations are major events associated with mitochondrial dysfunction and represent critical initiating events in most forms of chronic liver disease.
Through creating an analogy with a disrupted electric circuit gone bad, the present review focuses initially on how hepatic mitochondrial bioenergetics is affected in the context of drug and disease-induced liver failure and how targeting mitochondria with several antioxidant agents can be helpful for preventing the disruption of the mitochondrial electric circuit.
Keywords: Alcohol, cholestasis, drug-induced liver injury, ischemia-reperfusion, glutathione, liver diseases, medicinal chemistry, reactive oxygen species, oxidative stress, pharmacology, mitochondria
Current Medicinal Chemistry
Title: Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Volume: 18 Issue: 35
Author(s): C. V. Diogo, I. Grattagliano, P. J. Oliveira, L. Bonfrate and P. Portincasa
Affiliation:
Keywords: Alcohol, cholestasis, drug-induced liver injury, ischemia-reperfusion, glutathione, liver diseases, medicinal chemistry, reactive oxygen species, oxidative stress, pharmacology, mitochondria
Abstract: Mitochondria play a key role in intracellular energy-generating processes, cell life and death, and are heavily involved in several metabolic pathways by integrating signaling networks; thus, a very large number of conditions are characterized by mitochondrial bioenergetic in humans. Often, mitochondrial changes are directly or indirectly dependent on the activation of intracellular stress cascades or death receptor-mediated pathways. Reactive oxygen species (ROS) formation, glutathione (GSH) depletion, protein alkylation and respiratory complex alterations are major events associated with mitochondrial dysfunction and represent critical initiating events in most forms of chronic liver disease.
Through creating an analogy with a disrupted electric circuit gone bad, the present review focuses initially on how hepatic mitochondrial bioenergetics is affected in the context of drug and disease-induced liver failure and how targeting mitochondria with several antioxidant agents can be helpful for preventing the disruption of the mitochondrial electric circuit.
Export Options
About this article
Cite this article as:
V. Diogo C., Grattagliano I., J. Oliveira P., Bonfrate L. and Portincasa P., Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease, Current Medicinal Chemistry 2011; 18 (35) . https://dx.doi.org/10.2174/092986711798194432
DOI https://dx.doi.org/10.2174/092986711798194432 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coenzyme Q10 in Neurodegenerative Diseases
Current Medicinal Chemistry Gene Patents in the Primary Prevention of Vascular Diseases
Recent Patents on DNA & Gene Sequences Immunomodulatory Roles of VIP and PACAP in Models of Multiple Sclerosis
Current Pharmaceutical Design Generation of Human Cardiomyocytes for Cardiac Regenerative Therapies: Differentiation and Direct Reprogramming
Current Pharmaceutical Design Virus-Associated Vasculitides: An Update
Current Immunology Reviews (Discontinued) Radioligands for the Angiotensin II Subtype 1 (AT1) Receptor
Current Topics in Medicinal Chemistry Compounds that Combine Aldose Reductase Inhibitory Activity and Ability to Prevent the Glycation (Glucation and/or Fructation) of Proteins as Putative Pharmacotherapeutic Agents
Drug Design Reviews - Online (Discontinued) Therapeutic Potential and Mechanisms of Action of Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome
Current Stem Cell Research & Therapy Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews Protecting the Heart: Biological Targets and Clinical Strategies
Current Pharmaceutical Design The C-Reactive Protein Levels in Left Ventricular Dysfunction of Different Etiology
Inflammation & Allergy - Drug Targets (Discontinued) TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets Proteomics to Identify Novel Biomarkers and Therapeutic Targets in Cardiovascular Disease
Letters in Drug Design & Discovery Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology The Resurgence of Aldosterone in Hypertension and Cardiovascular Disease
Current Hypertension Reviews The Role of Transcription Factors in the Formation of an Arrhythmogenic Substrate in Congestive Human Heart Failure
Current Medicinal Chemistry Editorial [Hot Topic : Current Practice and trends in echocardiography in Critical Care, Anesthesiology and Emergency Medicine (Guest Editor: Paulo Marcelino)]
Current Cardiology Reviews Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry The Role of Toll-Like Receptor Pathways in the Mechanism of Type 1 Diabetes
Current Molecular Medicine A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design